You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Optimizing Direct Delivery of Nucleic Acid Therapeutics

    SBC: FHC, INC.            Topic: NIMH

    Project Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps

    SBC: Contech Medical, Inc.            Topic: NICHD

    Project Summary Abstract We propose a new approach to the decontamination of central venous catheters and the prevention of central line associated bloodstream infectionsCLABSIan important healthcare associated infectionCLABSIs cost the US healthcare system approximately $billion annuallyPronovostNEJMAdditionallyCLABSIs can be life threateningespecially in the very young and critically illEven whe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Galectin-1 Protein Therapy for Congenital Muscular Dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    Abstract Lamininrelated congenital muscular dystrophyLAMACMDalso known as Merosin Deficient Congenital Muscular DystrophyMDC Ais a fatal muscle wasting disease that affects patients from birthLAMACMD results from mutations in the LAMAgene resulting in loss of lamininproteinLamininis required for the formation of the heterotrimers lamininand lamininwhich are major constituents of the skeletal and c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement

    SBC: R. M. BEAUMONT CORPORATION            Topic: NIA

    DESCRIPTION provided by applicant Osteoarthritis OA diagnosed in over of the US population is the primary cause of musculoskeletal lower extremity disability Although there is no cure exercise remains the core treatment to manage OA regardless of age comorbidity pain severity or disability Yet many people with this condition do not engage in regular fitness and thus may resort t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government